Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)
0:00
10:26
Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Otros episodios de "The Lancet Respiratory Medicine in conversation with"
No te pierdas ningún episodio de “The Lancet Respiratory Medicine in conversation with”. Síguelo en la aplicación gratuita de GetPodcast.